QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy

QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test to Detect COVID-19 Under New FDA Policy

Shots:

  • QIAGEN has started the shipment of its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to the US for diagnosing the patients infected with COVID-19 under a new FDA’s policy, announced on Mar 16, 2020
  • The QIAstat-Dx test is a multiplexed nucleic acid test that assesses samples such as nasopharyngeal swabs obtained from individuals suspected of the respiratory tract and can differentiate the SARS-CoV-2 from 20 other respiratory infections
  • The kit requires < 1min. for preparing the sample and delivers results in ~1hr. The company is expected to submit EUA to the US FDA this week

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: QIAGEN